Megan Chavez, PA
Physician Assistant · McAllen, TXNPI 1386265783
Payments from drug & device makers
Across 1,250 payments — averaging $16.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$3K
- Otsuka America Pharmaceutical, Inc.$3K
- AbbVie$3K
- Alkermes, Inc.$2K
- Neurocrine Biosciences, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- plus $7K from 21 others
What the payments were for
- Food & beverage$20,11499%
- Education$2341%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 183 | $2,781 |
| Otsuka America Pharmaceutical, Inc. | 167 | $2,665 |
| AbbVie | 219 | $2,535 |
| Alkermes, Inc. | 100 | $1,965 |
| Neurocrine Biosciences, Inc. | 86 | $1,948 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 138 | $1,634 |
| Supernus Pharmaceuticals, Inc. | 72 | $1,184 |
| Lundbeck LLC | 45 | $1,008 |
| Corium, LLC | 41 | $802 |
| E.r. Squibb & Sons, L.L.C. | 28 | $775 |
| Ironshore Pharmaceuticals Inc. | 32 | $742 |
| Johnson & Johnson | 45 | $688 |
| Axsome Therapeutics, Inc. | 22 | $461 |
| Vanda Pharmaceuticals Inc. | 7 | $214 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $207 |
| Idorsia Pharmaceuticals US Inc | 19 | $162 |
| Collegium Pharmaceutical, Inc. | 6 | $109 |
| Tris Pharma Inc | 5 | $102 |
| Eisai Inc. | 6 | $95 |
| Indivior Inc. | 3 | $58 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $58 |
| Acadia Pharmaceuticals Inc | 2 | $41 |
| Merck | 2 | $30 |
| Sunovion Pharmaceuticals Inc. | 3 | $27 |
| Almatica Pharma LLC | 1 | $26 |
| Phadia US Inc. | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$2,473
- ARISTADA$957
- INGREZZA$386
- Austedo XR$350
- VRAYLAR$344
- ABILIFY MAINTENA$128
- ABILIFY ASIMTUFII$128
- Auvelity$125
- Azstarys$124
- JORNAY PM$123
- Fanapt$121
- COBENFY$120
- REXULTI$120
- UZEDY$119
- ARISTADA INITIO$114
- OPDIVO$106
How this compares
$20,348 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 415 | $601,468 |
| IngrezzaValbenazine Tosylate | 68 | $581,211 |
| AustedoDeutetrabenazine | 32 | $304,621 |
| RexultiBrexpiprazole | 175 | $274,308 |
| TrintellixVortioxetine Hydrobromide | 303 | $165,967 |
| Austedo XrDeutetrabenazine | 15 | $163,558 |
| Invega SustennaPaliperidone Palmitate | 38 | $129,833 |
| Abilify MaintenaAripiprazole | 42 | $121,698 |
| AristadaAripiprazole Lauroxil | 36 | $118,092 |
| Invega TrinzaPaliperidone Palmitate | 11 | $110,222 |
| CaplytaLumateperone Tosylate | 61 | $106,111 |
| BelsomraSuvorexant | 140 | $62,905 |
| Lurasidone Hcl | 364 | $59,562 |
| LybalviOlanzapine/Samidorphan Malate | 34 | $51,397 |
| Risperdal ConstaRisperidone Microspheres | 13 | $36,262 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Namzaric, Fetzima | $2,535 | $631,031456 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,948 | $581,21168 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $2,781 | $468,17947 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $2,665 | $396,006217 claims |
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta, Spravato | $688 | $292,66775 claims |
| Alkermes, Inc.Aristada, Lybalvi | $1,965 | $169,48970 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $207 | $165,967303 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,634 | $106,11161 claims |
| MerckBelsomra | $30 | $62,905140 claims |
| Eisai Inc.Dayvigo | $95 | $13,52455 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $162 | $10,50621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.
Other physician assistant in McAllen
- Cynthia TrickettDallas$1.3M
- Kristine KuceraMelissa$797K
- Selina SantosAustin$543K
- Matthew BrunoMcKinney$538K
- Anthony DerenciusSan Antonio$507K
- Brooke HodnickSouthlake$479K
- Holly GloverArlington$418K
- Kirk GautierAthens$416K
- Jaime RomanPlano$338K
- Michael WhiteDallas$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.